Fredrik Holmquist

Fredrik Holmquist

Auto-generated profile, based on publicly available information

Fredrik Holmquist

Department of Medical Imaging and Physiology, Skåne University Hospital, Lund, Sweden

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2023 in European Journal of Surgical Oncology
Verified
Journal Article
Open access
PFPetter Frühling
Petter Frühling
DSDavid Stillström
David Stillström
FHFredrik Holmquist
Fredrik Holmquist
ANAnders Nilsson
Anders Nilsson
JFJacob Freedman
Jacob Freedman
A nationwide multicenter study was performed to examine short- and long-term effects of irreversible electroporation (IRE) for hepatocellular carcinoma (HCC) and colorectal cancer liver metastases (CRCLM). IRE is an alternative method when thermal ablation is contraindicated because of risk for serious thermal complications. All consecutive patients in Sweden treated with IRE because of HCC or CRCLM, were included between 2011 and 2018. We evaluated medical records and radiological imaging to obtain information regarding patient-, tumor-, and treatment characteristics. We also assessed local tumor progression, and survival. In total 206 tumors in 149 patients were treated with IRE. Eighty-seven patients (58.4%) had colorectal cancer liver metastases, and 62 patients (41.6%) had hepatocellular carcinoma. Median tumor size was 20 mm (i.q.r. 14-26 mm). Median overall survival for CRCLM and HCC, were 27.0 months (95% CI 22.2-31.8 months), and 35.0 months (95% CI 13.8-56.2 months), respectively. Median follow-up time was 58 months (95% CI 50.6-65.4). Local ablation success at six and twelve months for HCC was 58.3% and 40.3%, and for CRCLM 37.7% and 25.4%. The median time to local tumor progression (LTP) for HCC was 21.0 months (95% CI: 9.5-32.5 months), and for CRCLM 6.0 months (95% CI: 4.5-7.5 months). At 30-day follow-up, 15.4% (n = 23) of patients suffered from a complication rated as Clavien-Dindo grade 1-3a. Three patients (2.0%) had grade 3b-5 with one death in a thromboembolic event. IRE is a safe ablation modality for patients with liver tumors that are located in such a way that other treatment options are unsuitable.

21 July 2016 in Acta Radiologica
Verified
Journal Article
Closed access
PDF file
FHFredrik Holmquist
Fredrik Holmquist
UNUlf Nyman
Ulf Nyman
RSRoger Siemund
Roger Siemund
MGMats Geijer
Mats Geijer
MSMarcus Söderberg
Marcus Söderberg
Background: Low kilovoltage (kVp) computed tomography (CT) may be used to reduce contrast medium dose in patients at risk of contrast nephropathy, at the cost of increased image noise. Purpose: To evaluate: (i) the impact of iterative reconstructions (Siemens SAFIRE) on low-contrast object detection to compensate for increased noise instead of increased tube loading when decreasing tube potential; and (ii) the change in iodine attenuation in simulated abdominal CT. Material and Methods: A phantom was scanned at 70, 80, 100, and 120 kVp at fixed effective tube loading (170 mAsEFF) and fixed radiation dose (CTDIVOL 10 mGy). Images were reconstructed with filtered back-projection (FBP) and SAFIRE strengths S1–S5. Iodine attenuation, objective image noise, contrast-to-noise ratio (CNR), noise power spectrum (NPS), spatial resolution, and subjective detectability of low-contrast objects were evaluated. Results: Compared with 120 kVp iodine attenuation increased by a factor 1.6 and 2.0, and image noise increased by a factor 1.9 and 2.5 at 80 and 70 kVp, respectively. Compared with FBP, SAFIRE showed objective reduction in image noise and increased CNR without loss of spatial resolution or any significant NPS alteration, with general tendency to improve subjective detectability of low-contrast objects. At 170 mAsEFF the number of discernible 1.0% contrast objects at 70 kVp/S5 and 80 kVp/S5 was similar to that at 120 kVp/FBP. Conclusion: With the SAFIRE algorithm image noise, CNR and detectability of low-contrast objects may be kept unchanged without increased tube loading when using low kVp settings to reduce contrast medium dose in azotemic patients.

12 March 2024 in Journal of Applied Clinical Medical Physics
Verified
Journal Article
Open access
EFErik Baubeta Fridh
Erik Baubeta Fridh
EGEva Laurin Gadsböll
Eva Laurin Gadsböll
LWLeon Will
Leon Will
FHFredrik Holmquist
Fredrik Holmquist
MAMarie‐Louise Aurumskjöld
Marie‐Louise Aurumskjöld
Purpose: This study aimed to elucidate whether gadolinium contrast in clinically relevant doses can be used with photon‐counting computed tomography (PCCT) as an alternative contrast agent in clinical applications.Material/methods: A CTDI phantom with 3D printed rods filled with different concentrations of gadolinium and iodine contrast was scanned in a PCCT and an energy‐integrated computed tomography (EICT). Attenuation values at different monoenergetic steps were extracted for each contrast concentration.Results: For PCCT, gadolinium reached an attenuation >100 HU (103 HU) at 40 keV with a concentration 5 mmol/L whereas the same level was reached at 50 keV (118 HU) for 10 mmol/L and 90 keV (114 HU) for 25 mmol/L. For iodine, the same level of attenuation was reached at 100 keV (106 HU) with a concentration 8.75 mg I/mL.For EICT the lowest gadolinium contrast concentration needed to reach >100 HU (108 HU) was 10 mmol/L at 50 keV. For 25 mmol/L 100 HU was reached at 100 keV. For iodine contrast 108 HU was reached at 110 keV for 8.75 mg I/mL.Conclusion: No K‐edge potential or difference in attenuation curves between iodine and gadolinium contrast is detected on the first clinical available PCCT. Clinically relevant attenuation levels were barely achieved in this setting with gadolinium concentrations approved for human use. The results of this study suggest that, given current scanning technology, gadolinium is not a clinically useful contrast agent for computed tomography because no K‐edge was detected.

14 August 2024 in Acta Radiologica
Verified
Journal Article
Closed access
EGEva Laurin Gadsbøll
Eva Laurin Gadsbøll
MAMarie-Louise Aurumskjöld
Marie-Louise Aurumskjöld
FHFredrik Holmquist
Fredrik Holmquist
EBErik Baubeta
Erik Baubeta
Background: Photon-counting computed tomography (PCCT) enables new ways of image reconstruction, e.g. material decomposition and creation of virtual non-contrast (VNC) series with higher resolution and lower radiation dose than standard computed tomography (CT). Clinical experiences of this are limited. Purpose: To compare true non-contrast (TNC) series with VNC series derived from non-enhanced (VNCu), arterial phase (VNCa) and portal venous phase (VNCv) in clinically approved PCCT. Material and Methods: A total of 45 clinical, tri-phasic abdominal CT scans from the PCCT Naetom Alpha, between February 2022 and November 2022, were retrospectively assessed. Placing a region of interest in six different locations in each VNC series – right liver parenchyma, left liver parenchyma, spleen, aorta, erector spinae muscle, and in the subcutaneous fat – absolute Hounsfield values (HU) and standard deviations (SD) were collected. Differences in HU (ΔHU) were compared and statistically analyzed. Results: Statistically significant differences between VNC and TNC were seen in all measurements, with the largest difference in the subcutaneous fat and the smallest difference in the erector spinae muscle. Only small differences were seen between VNCa and VNCv, where the largest differences were seen in the left and right liver lobes. Conclusion: VNC images from the first-generation clinically approved PCCT showed a significant difference between VNC and TNC images. The differences vary with the type of tissue. Only small differences were seen depending from which contrast phase the VNC was derived.

22 October 2023 in Heliyon
Verified
Journal Article
Open access
DBDennis Björk
Dennis Björk
MDMartin Delle
Martin Delle
FHFredrik Holmquist
Fredrik Holmquist
KHKristina Hasselgren
Kristina Hasselgren
PSPer Sandstrom
Per Sandstrom
BBBergthor Björnsson
Bergthor Björnsson
An adequate future liver remnant (FLR) is fundamental for major liver resections. To achieve sufficient FLR, portal vein embolization (PVE) may be used. The most effective material for PVE has yet to be determined. The aim of this study was to investigate the differences in FLR growth between n-butyl-cyanoacrylate glue (NBCA) and microparticles. retrospective study was performed at three Swedish hepatobiliary centers and included patients who underwent PVE 2013–2021. Electronic medical records were reviewed, and procedure-related data were collected. Data were analyzed with respect to embolizing material. A total of 265 patients were included: 160 in the NBCA group and 105 in the microparticle group. The NBCA group had a higher degree of hypertrophy (12.1 vs. 9.4 % points, p = 0.003) and a higher resection rate (68 vs. 59 %, p = 0.01) than the microparticle group. Procedure-related data all indicated the superiority of NBCA. No difference in inducing hypertrophy was observed when comparing patients who received chemotherapy before PVE with those who received chemotherapy before and after PVE within the NBCA group. This retrospective multicenter study supports the superiority of NBCA compared to microparticles in the setting of PVE. Chemotherapy after PVE does not seem to negatively affect hypertrophy.

3 August 2019 in Acta Radiologica
Verified
Journal Article
Open access
PDF file
FHFredrik Holmquist
Fredrik Holmquist
MSMarcus Söderberg
Marcus Söderberg
UNUlf Nyman
Ulf Nyman
TFTobias Fält
Tobias Fält
RSRoger Siemund
Roger Siemund
MGMats Geijer
Mats Geijer
Background: Low peak kilovoltage (kV p ) computed tomography (CT) may be used to reduce contrast medium doses in patients at risk of contrast medium-induced acute kidney injury if image noise can be controlled by increasing X-ray tube loading (mAs). Purpose: To evaluate objective and subjective image quality in 80-kV p CT with reduced contrast medium dose and compensated mAs for unchanged image noise in patients with estimated glomerular filtration rate <45 mL/min compared with the standard 120-kV p protocol. Material and Methods: 80-kV p CT with 300 mg I/kg in 40 patients (body mass index 18–32 kg/m 2 , glomerular filtration rate <45 mL/min) and 120-kV p CT with 500 mg I/kg in 40 patients (body mass index = 17–30 kg/m 2 , glomerular filtration rate ≥45 mL/min) was compared on mean hepatic attenuation, image noise, contrast medium enhancement, signal-to-noise ratio, contrast-to-noise ratio, effective radiation dose, and subjective image quality. Results: There were no significant differences regarding median hepatic post-contrast attenuation, image noise, contrast medium enhancement, signal-to-noise ratio, contrast-to-noise ratio, or effective dose between the 80-kV p and 120-kV p cohorts: 114/110 HU; 14/14 HU; 57/53 HU; 8.0/7.4; 3.8/3.5; and 5.3/5.9 mSv, respectively. However, subjective image visual grading showed statistically significantly inferior scores for 80 kV p for six of eight items. After exclusion of seven inferior examinations not caused by the chosen kV p technique, only three items showed inferior scores for 80 kV p . Only 5% of gradings regarding overall image quality were <3 of 5 points. Conclusion: Despite lower subjective image quality, objective data indicate that 80-kV p CT with reduced contrast medium doses and compensated mAs may have the potential to provide satisfactory diagnostic quality in patients with body mass index <30 kg/m 2 , which could benefit patients at risk of contrast medium-induced acute kidney injury.